influenza
epidem
associ
nontrivi
morbid
mortal
one
billion
infect
occur
annual
upward
half
million
associ
death
mortal
associ
first
influenza
pandem
centuri
caus
swineorigin
influenza
viru
high
first
anticip
compar
pandem
claim
estim
million
live
worldwid
howev
continu
risk
lethal
transmiss
influenza
pandem
gener
widespread
warrant
concern
three
genera
influenza
viru
infect
human
influenza
b
c
virus
type
influenza
virus
virul
influenza
virus
infect
human
divid
differ
subtyp
basi
antigen
properti
virion
surfac
protein
hemagglutinin
ha
neuraminidas
na
current
ha
subtyp
na
subtyp
identifi
possibl
combin
found
circul
wild
bird
howev
major
influenza
human
caus
three
subtyp
ha
two
subtyp
na
inde
recent
pandem
caus
three
subtyp
name
spanish
swine
flu
pandem
respect
known
asian
flu
known
hong
kong
flu
contrast
influenza
virus
b
virus
mutat
slowli
present
two
antigen
distinct
type
b
influenza
lineag
victoria
yamagata
concurr
circul
individu
expos
one
lineag
limit
crossprotect
immun
antigen
dissimilar
strain
burden
diseas
due
influenza
b
viral
infect
fall
larg
children
young
adult
influenza
viru
caus
season
influenza
epidem
everi
year
contrast
influenza
c
viru
although
common
caus
mild
upper
respiratori
ill
rare
caus
sever
ill
local
epidem
peopl
acquir
protect
antibodi
earli
life
southern
hemispher
routin
formul
contain
two
human
influenza
subtyp
one
two
influenza
b
lineag
yamagata
victoria
mani
countri
implement
influenza
healthcar
strategi
vaccin
administ
discret
popul
cohort
risk
complic
young
elderli
global
burden
influenza
diseas
mainli
occur
infant
age
year
account
million
infect
annual
children
shed
viru
high
rate
routin
congreg
high
number
exampl
school
nurseri
thu
facilit
easi
dissemin
viru
famili
member
turn
wider
public
question
whether
mass
vaccin
young
children
influenza
point
consider
debat
among
clinic
immunolog
public
health
commun
present
clear
consensu
support
vaccin
children
influenza
argu
confer
protect
segment
societi
benefit
children
also
benefit
wider
adult
popul
opposit
healthcar
strategi
hing
idea
individu
includ
children
may
accru
better
heterosubtyp
immun
natur
exposur
influenza
viru
oppos
vaccin
heterosubtyp
crossclad
memori
broadli
classifi
protect
induc
influenza
subtyp
strain
confer
protect
strain
mediat
humor
cellular
immun
approxim
influenzarel
death
outsid
pandem
set
occur
among
peopl
age
year
older
heighten
suscept
increas
individu
age
person
age
year
older
time
like
die
influenzarel
death
compar
age
year
progress
declin
immun
system
thought
principl
caus
increas
suscept
infect
older
adult
agerel
declin
immun
respons
immunosenesc
affect
innat
adapt
immun
respons
although
influenza
vaccin
undoubtedli
save
numer
live
pandem
epidem
outbreak
remain
consider
variat
influenza
vaccin
use
efficaci
achiev
target
popul
cohort
influenza
associ
complic
still
repres
consider
global
healthcar
burden
instanc
healthi
adult
efficaci
inactiv
vaccin
estim
wherea
children
age
year
efficaci
associ
trival
influenza
vaccin
tiv
vaccin
compar
placebo
elderli
valid
use
inactiv
influenza
vaccin
question
recent
systemat
review
assert
conclus
evid
regard
efficaci
effect
influenza
vaccin
peopl
age
year
older
compar
inactiv
vaccin
efficaci
live
vaccin
children
consider
higher
approxim
howev
live
vaccin
also
associ
low
effect
approxim
moreov
laiv
licens
children
year
age
associ
increas
risk
associ
wheez
adult
age
year
laiv
licens
owe
lack
corrobor
efficaci
thu
clear
need
develop
effect
efficaci
influenza
vaccin
infant
elderli
abl
howev
must
understand
factor
underpin
current
limit
licens
influenza
vaccin
humor
immun
respons
current
licens
influenza
vaccin
induc
rel
narrow
adapt
immun
respons
limit
crossclad
immun
crossclad
protect
refer
protect
immun
one
influenza
isol
subsequ
confer
protect
efficaci
upon
exposur
differ
isol
major
humor
respons
follow
influenza
vaccin
direct
toward
ha
princip
toward
globular
head
domain
found
segment
due
constantli
evolv
mutat
propens
ha
neutral
antibodi
offer
littl
protect
subtyp
even
strain
case
appear
detriment
consider
disadvantag
consid
influenza
undergo
antigen
drift
antigen
shift
antigen
drift
refer
small
gradual
chang
occur
point
mutat
ha
na
code
gene
antigen
shift
refer
abrupt
major
alter
gener
produc
subtyp
chang
occur
either
direct
animaltohuman
transmiss
reassort
human
anim
influenza
escap
mutant
contain
mutat
globular
head
domain
region
protein
contain
widespread
immunodomin
decoy
domain
readili
mutat
without
significantli
affect
viru
fit
thu
yearli
vaccin
reformul
vaccin
requir
antigen
differ
occur
even
within
influenza
strain
natur
exposur
influenza
thought
induc
broad
immun
respons
induc
crossclad
protect
tand
bcell
respons
inde
antibodi
direct
stalk
region
ha
previous
shown
confer
broadspectrum
protect
toward
differ
influenza
isol
annual
vaccin
tiv
thought
rel
poor
induc
crossclad
immun
respons
cellular
immun
respons
cellular
immun
respons
thought
play
import
protect
role
influenza
infect
human
challeng
studi
demonstr
neg
correl
tcell
respons
viral
antigen
influenza
diseas
tcell
respons
particularli
rel
wellconserv
intern
influenza
antigen
efficaci
provid
crossclad
protect
although
human
cytotox
tlymphocyt
ctl
immun
declin
period
low
influenza
preval
cell
still
detect
year
estim
halflif
year
make
cell
ideal
target
boost
vaccin
although
cellular
immun
prevent
viral
infect
import
clear
curtail
infect
cytotox
cell
play
major
role
elimin
viral
infect
cell
direct
cytolyt
role
cell
demonstr
importantli
cell
provid
bcell
help
prior
tcell
immun
efficaci
augment
haspecif
antibodi
respons
unfortun
even
though
inactiv
influenza
vaccin
routin
contain
intern
influenza
antigen
specif
nucleoprotein
matrix
protein
vaccin
boost
cellular
immun
efficaci
level
predict
major
circul
influenza
subtyp
basi
routin
surveillancerequir
updat
influenza
vaccin
yearcan
fail
inde
mismatch
vaccin
compon
circul
viru
occur
approxim
everi
year
mismatch
signific
effect
vaccin
efficaci
healthi
adult
parenter
vaccin
efficaci
season
influenza
approxim
circul
influenza
vaccin
strain
match
howev
efficaci
decreas
mismatch
occur
substanti
cost
incur
need
annual
reformul
given
manufactur
process
recent
pandem
took
month
even
implement
pandem
readi
plan
year
essenti
race
product
deploy
spread
infect
one
main
challeng
induc
strong
immun
respons
follow
vaccin
inactiv
subunit
protein
vaccin
inher
poor
immunogen
protein
partial
overcom
addit
adjuv
adjuv
common
mean
augment
adapt
immun
respons
vaccin
broadli
classifi
vehicl
immunostimul
former
group
larg
enhanc
present
immun
system
wherea
latter
enhanc
adapt
immun
respons
adjuv
shown
advantag
increas
broaden
epitop
recogn
immun
repertoir
number
strategi
deploy
improv
influenza
vaccin
efficaci
elderli
inclus
adjuv
mean
augment
humor
immun
elderli
demonstr
rel
encourag
result
anoth
challeng
longterm
stabil
recombin
protein
inclus
adjuv
facilit
increas
vaccin
stabil
storag
upon
inject
howev
even
augment
stabil
often
thermost
difficulti
especi
vaccin
occupi
larg
amount
coldchain
storag
space
due
rel
complex
administr
dose
regimen
number
platform
explor
efficaci
influenza
vaccin
deliveri
broadli
classifi
recombin
protein
peptid
dna
vaccin
viruslik
particl
virosom
viral
vector
recombin
technolog
use
gener
influenza
protein
insect
cell
bacteria
plant
although
much
antigen
produc
protein
gener
poorli
immunogen
requir
complex
immun
regim
andor
inclus
adjuv
induc
efficaci
humor
immun
cellular
immun
respons
antigen
map
tcell
epitop
follow
antigen
string
deliveri
form
peptid
activ
investig
unfortun
peptid
gener
poorli
immunogen
repeat
administr
augment
adapt
immun
respons
induc
toler
rather
immunogenc
immun
dna
encod
influenza
protein
studi
mani
year
altern
vaccin
strategi
clinic
trial
met
limit
success
dna
vaccin
boost
preexist
immun
scenario
adult
human
popul
gener
weakli
immunogen
human
selfassembl
viral
capsid
protein
viruslik
particl
vlp
produc
number
virus
key
restrict
certain
vlp
platform
small
size
foreign
epitop
accommod
exampl
ha
rel
big
protein
gener
vlp
appropri
protein
glycosyl
correct
assembl
eas
purif
need
consid
concern
may
dictat
use
mammalian
cell
cultur
system
less
control
costli
system
although
similar
vlp
mani
respect
virosom
contrast
essenti
assembl
vitro
limit
number
virosomaladjuvantedsubunit
influenza
vaccin
current
licens
gener
vaccin
requir
good
manufactur
practic
gmp
grade
influenza
viru
vaccin
face
similar
obstacl
product
tiv
vector
vaccin
recombin
liveattenu
replicationdefici
virus
current
develop
vaccin
deliveri
offer
number
advantag
emerg
technolog
viral
vector
vaccin
particularli
good
express
fulllength
protein
gener
conform
restrict
epitop
thu
drive
potent
humor
respons
follow
immun
addit
vector
vaccin
induc
high
level
protect
cellular
immun
thu
viral
vector
efficaci
induc
arm
adapt
immun
system
follow
vaccin
viral
vector
vaccin
viru
infect
local
cell
produc
high
level
protein
follow
vaccin
modest
amount
viral
vector
viral
particl
vp
adenoviru
plaqueform
unit
pfu
modifi
vaccinia
viru
ankara
antigen
detect
immun
site
month
viral
vector
vaccin
contrast
transient
antigen
depot
follow
protein
vaccin
even
coadminist
adjuv
increas
presenc
antigen
may
enhanc
surviv
certain
memori
cell
augment
highaffin
antibodi
select
viral
infect
result
apoptosi
necrosi
local
tissu
facilit
releas
antigen
subsequ
avail
drive
cellular
humor
immun
associ
cell
death
follow
viral
infect
also
advantag
augment
adapt
immun
respons
circumv
need
inclus
adjuv
live
recombin
viral
vector
must
remain
infecti
effect
convent
continu
refriger
requir
maintain
stabil
viabil
howev
recent
methodolog
allow
complet
recoveri
viral
titer
immunogen
storag
month
addit
viral
vector
vaccin
rel
easi
manipul
produc
wellestablish
safeti
profil
increas
number
viralbas
vector
current
employ
antigen
deliveri
system
includ
dna
viru
vector
exampl
poxvirus
herpesviru
adenoviru
baculoviru
rna
viru
vector
exampl
paramyxoviru
rhabdoviru
bunyaviru
alphaviru
coronaviru
retroviru
flaviviru
howev
major
human
clinic
trial
assess
viral
vector
influenza
vaccin
use
poxvir
adenovir
technolog
vector
consid
lead
candid
immunogen
deliveri
antigen
adenovirus
ad
nonenvelop
dna
virus
origin
identifi
infecti
agent
respons
certain
acut
respiratori
infect
ad
infect
usual
manifest
mild
diseas
promptli
resolv
howev
infect
immunocompromis
individu
result
sever
diseas
sever
properti
ad
virus
attract
vaccin
use
includ
rel
eas
manipul
infect
divid
nondivid
cell
high
level
transgen
express
abil
grow
high
titer
vitro
lack
integr
host
genom
stabil
physic
genet
ad
render
replic
defect
delet
region
gene
although
replic
compet
ad
vector
demonstr
quantit
reduct
requir
dose
qualit
induct
sitespecif
immun
effect
releas
genet
modifi
ad
vector
gener
public
fuell
concern
possibl
carriag
limit
systemat
use
nonrepl
human
ad
exampl
vector
extens
use
gene
therapi
applic
unfortun
adult
high
titer
neutral
antibodi
number
ad
serotyp
includ
neg
impact
effect
vaccin
platform
circumv
limit
altern
serotyp
adenoviru
found
human
popul
develop
includ
ad
rare
serotyp
nonhuman
ad
princip
chimpanze
origin
adc
addit
engin
chimer
vector
capsid
modifi
therebi
reduc
number
antigen
epitop
previous
seen
man
also
deploy
number
vaccin
studi
demonstr
feasibl
use
recombin
ad
vector
express
influenza
viral
protein
protect
model
organ
influenza
challeng
recombin
ad
vector
express
ha
induc
cellular
humor
immun
protect
follow
lethal
challeng
mice
chicken
heterosubtyp
immun
toward
certain
influenza
virus
induc
ovo
vaccin
nonrepl
ad
vector
express
ha
inde
longlast
immun
month
postimmun
demonstr
follow
ad
vaccin
applic
ad
viral
vector
vaccin
progress
human
studi
phase
clinic
trial
use
nonrepl
adenoviru
vector
nasal
administ
influenza
vaccin
demonstr
vaccin
well
toler
efficaci
induc
humor
immun
followon
trial
evalu
dose
rang
safeti
immunogen
intranas
administ
adenoviru
vector
ha
healthi
adult
year
age
expect
complet
immin
clinicaltrialsgov
identifi
replic
compet
ad
vector
gener
induc
stronger
immun
respons
live
replic
compet
recombin
ad
vector
vaccin
express
ha
administ
either
intranas
tonsillarli
phase
random
doseescal
studi
expect
complet
clinicaltrialsgov
identifi
poxvirus
among
heavili
exploit
viral
vector
larg
overwhelm
success
vaccinia
viru
erad
smallpox
larg
dna
virus
poxvirus
easili
accommod
substanti
amount
kb
extra
dna
thu
facilit
multival
vaccin
approach
simultan
express
multipl
transgen
poxvirus
replic
within
cytoplasm
infect
cell
integr
host
genom
elimin
potenti
insert
mutagenesi
develop
vaccin
two
differ
approach
first
reli
product
replic
attenu
strain
permiss
host
second
use
replicationdefect
poxvirus
may
enter
cell
nonpermiss
host
express
encod
protein
produc
infecti
viru
modifi
vaccinia
viru
ankara
mva
attenu
strain
vaccinia
viru
origin
develop
smallpox
erad
campaign
wildtyp
strain
produc
undesir
effect
human
attenu
vaccinia
strain
mva
undergo
limit
nonproduct
replic
mammalian
cell
although
viru
protein
produc
includ
insert
transgen
mva
excel
safeti
profil
human
use
mani
field
studi
safeti
also
demonstr
studi
immunocompromis
macaqu
human
one
ongo
concern
viral
vector
vaccin
applic
repeat
vaccin
preclin
evalu
mva
vector
demonstr
abil
repeatedli
boost
immun
respons
direct
recombin
antigen
inde
two
phase
clinic
trial
use
repeat
vaccin
mva
vector
vaccin
month
demonstr
abil
boost
tcell
respons
data
suggest
vectorspecif
immun
greatli
imped
immun
respons
toward
target
antigen
major
advantag
mva
vaccin
prepar
adjuv
requir
high
immunogen
mva
immunostimulatori
properti
elicit
potent
humor
antigenspecif
tcell
respons
effici
activ
tcell
respons
mva
vector
deliveri
full
length
antigen
gener
found
superior
suggest
crossprim
may
particularli
import
mvamedi
tcell
respons
bodi
evid
demonstr
recombin
poxvir
vector
express
influenza
antigen
efficaci
vaccin
inde
licens
poxvir
influenza
vaccin
trovac
aiv
prevent
influenza
chicken
vaccin
use
fowlpox
viru
encod
ha
gene
demonstr
protect
efficaci
wide
rang
highli
pathogen
virus
preclin
work
demonstr
feasibl
use
mva
vector
influenza
antigen
vaccin
mammal
mice
vaccin
mva
recombin
express
ha
fulli
protect
infect
homolog
strain
also
infect
virus
differ
clade
pentaval
vaccina
vaccin
ha
na
nucleoprotein
matrix
protein
abl
confer
steril
crossclad
protect
stringent
challeng
studi
studi
higher
primat
assess
feasibl
use
mvaexpress
hemagglutinin
influenza
vaccin
immun
avietnam
induc
crossreact
antibodi
prevent
viru
replic
respiratori
tract
cynomolgu
macaqu
inde
recent
phase
clinic
trial
assess
mva
vector
encod
nucleoprotein
matrix
protein
mvanp
demonstr
vaccin
safe
importantli
immunogenicinduc
high
level
interferon
ifn
product
tcell
promis
avenu
influenza
vaccin
develop
like
come
viral
vector
vaccin
current
progress
phase
ii
clinic
trial
design
produc
antiinfluenza
respons
vector
vaccin
demonstr
promis
immunogen
good
safeti
profil
like
vaccin
use
primeboost
regim
aim
augment
protect
immun
regim
involv
prime
adapt
immun
respons
toward
antigen
target
vaccin
vector
encod
antigen
choic
follow
boost
antigen
target
administ
differ
vector
immun
respons
hone
toward
antigen
choic
avoid
boost
antivector
immun
primeboost
approach
incorpor
prime
either
plasmid
dna
vaccin
viral
vector
typic
ad
follow
boost
either
adrecombin
mva
express
gene
product
shown
enhanc
protect
efficaci
inde
use
heterolog
regimen
ad
vector
vaccin
boost
mva
shown
augment
antigenspecif
tcell
respons
also
efficaci
induc
humor
immun
support
evid
evolv
like
outcom
use
viral
vector
vaccin
primeboost
regim
gener
strong
potenti
heterosubtyp
immun
respons
inde
heterosubtyp
immun
toward
certain
influenza
virus
induc
ovo
vaccin
nonrepl
ad
vector
express
ha
furthermor
vaccin
mva
recombin
express
ha
confer
protect
infect
homolog
strain
also
virus
differ
clade
induct
efficaci
longlast
crossclad
immun
respons
bypass
need
annual
vaccin
reformul
immun
importantli
provid
protect
futur
influenza
pandem
despit
longstand
servic
current
licens
influenza
vaccin
carri
number
real
limit
need
address
populationbas
influenza
vaccin
strategi
optim
undoubtedli
vaccin
induc
durabl
sustain
crossclad
protect
influenza
would
great
medicin
econom
benefit
worldwid
minimum
revis
current
vaccin
regim
atrisk
popul
need
consid
optim
health
outcom
improv
regim
like
includ
differ
vaccin
differ
age
man
children
fourprong
approach
includ
two
current
circul
influenza
subtyp
influenza
b
strain
suggest
wherea
elderli
inclus
two
current
circul
influenza
subtyp
influenza
b
strain
higher
dose
inclus
adjuv
augment
lower
respons
consid
undoubtedli
continu
concert
effort
invest
develop
efficaci
viral
vector
influenza
vaccin
deliv
promis
real
altern
current
deploy
greatli
impact
upon
public
health
centuri
lamb
oxford
martin
fellow
receiv
financi
support
medic
research
council
uk
oxford
biomed
research
centr
author
grate
gilbert
r
odonnel
help
comment
manuscript
author
declar
compet
interest
defin
molecular
medicin
interest
might
perceiv
influenc
result
discuss
report
paper
